Article Sidebar
Views pdf: 459
INITIAL RESULTF OF THE CONSOLIDATION THERAPY WITH DURVALUMAB AFTER CONCURRENT CHEMORADIOTHERAPY IN STAGE III NON – SMALL CELL LUNG CANCER IN PATIENTS AT K HOSPITAL
Main Article Content
Abstract
Aims: To evaluate the progression-free survival (PFS) and adverse events of consolidation therapy with Durvalumab after concurrent chemoradiotherapy in patients with stage III non-small cell lung cancer (NSCLC). Patients and Methods: This study included 46 patients with stage IIIA without surgery, IIIB, IIIC NSCLC who had not progressed after concurrent chemoradiotherapy, subsequently received consolidation therapy with Durvalumab for up to 12 months. Results: The mean age of the patients was 58.4 ± 7.1 years, male-to-female ratio of 1.8:1. The progression-free survival was 15,5 months. The most common adverse event was interstitial pneumonitis. Conclusion: This study on the first cohort of patients receiving Durvalumab consolidation therapy after chemoradiotherapy at K Hospital showed promising results in terms of progression-free survival, with manageable adverse effects.
Article Details
Keywords
Lung cancer, chemoradiotherapy, Durvalumab
References
2. David M Mannino, et al. Cigarette smoking and other possible risk factors for lung cancer - UpToDate. 13/03/2019.
3. Edge SB, American Joint Committee on Cancer, btv. AJCC cancer staging manual, Springer, New York. 2017
4. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990;323(14): 940-945. doi:10.1056/ NEJM199010043231403.